

## Molecular detection of virulence factors and biofilm formation in *Pseudomonas aeruginosa* obtained from different clinical specimens in Bandar Abbas

Nima Bahador<sup>2</sup>, Saeed Shoja<sup>1</sup>, Forough Faridi<sup>\*</sup>, Banafsheh Dozandeh-Mobarrez<sup>1</sup>,  
Fateme Izadpanah Qeshmi<sup>1</sup>, Sedigheh Javadpour<sup>1</sup>, Sedigheh Mokhtary<sup>2</sup>

<sup>1</sup>Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran

<sup>2</sup>Department of Microbiology, College of Sciences, Agriculture and Modern Technology, Shiraz Branch, Islamic Azad University, Shiraz, Iran

Received: October 2018 , Accepted: January 2019

### ABSTRACT

**Background and Objectives:** *Pseudomonas aeruginosa* is a ubiquitous opportunistic pathogen. The presence of several virulence factors such as exotoxin and exoenzyme genes and biofilm may contribute to its pathogenicity. The purpose of this study was to investigate the presence of *toxA*, *exoU* and *exoS*, the determination of biofilm production and antimicrobial susceptibility patterns among clinical isolates of *P. aeruginosa*.

**Materials and Methods:** In this study, 75 isolates of *P. aeruginosa* were recovered from various clinical specimens. Antimicrobial susceptibility pattern of isolates were identified. Virulence genes *toxA*, *exoU* and *exoS* were determined using PCR. The ability of biofilm production was assessed.

**Results:** Antimicrobial susceptibility test showed that 12 strains were resistant to more than 8 antibiotics (17.14%). The most effective antibiotic was colistin as 98.6% of isolates were sensitive. The frequencies of *exoU* and *exoS* genes were detected as 36.6% and 55.7%, respectively. In addition, 98.6% of the isolates were biofilm producers. Exotoxin A was detected in sixty-eight isolates (95.7%).

**Conclusion:** The findings of this study showed that, the presence of *P. aeruginosa* exotoxin and exoenzyme genes, particularly, the *exoU* gene is the most common virulence factors in the bacterial isolates from urine samples. Biofilm is a serious challenge in the treatment of *P. aeruginosa* infection.

**Keywords:** *Pseudomonas aeruginosa*; Virulence factors; Biofilm

### INTRODUCTION

*Pseudomonas aeruginosa* has emerged as an important nosocomial infection. This bacterium causes infection especially in the hosts with compromised defense mechanisms such as patients with severe burns and individuals with HIV infection (1-4). It causes a wide range of infections including septi-

\*Corresponding author: Forough Faridi, MSc, Infectious and Tropical Diseases Research Center, Hormozgan Health Institute, Hormozgan University of Medical Sciences, Bandar Abbas, Iran.

Tel: 076-33710372-3

Fax: 076-33710311

Email: forough.faridi@hums.ac.ir

cemia, pneumonia, endocarditis, burn wounds, otitis and keratitis (5, 6). *P. aeruginosa* is responsible for mortality rates as high as 50%. It may quickly become problematic once introduced in a hospital because of its ability to adhere to medical devices such as catheters (7). This organism is often resistant to antibiotics and enters the blood, causing septicemia (8). *P. aeruginosa* appears to be related to the production of a large number of secretions and cell-associated virulence factors including toxins, enzymes and biofilm (9). Growth in biofilm promotes bacterial survival. Once a biofilm is formed, it becomes extremely difficult to be destroyed (10). Biofilm is a complex aggregation of microorganisms in an exopolysaccharide matrix and is usually resistant to antibiotics (9). *P. aeruginosa* is a pathogen with innate resistance to many antibiotic classes and these include aminoglycosides, carbapenems, antipseudomonal penicillins, quinolones and cephalosporins. In addition, it has been known to acquire novel resistance genes via horizontal gene transfer (2, 11, 12). *P. aeruginosa* also possesses a variety of virulence factors such as exotoxin A (encoded by *toxA* gene), exoenzyme S (encoded by *exoS* gene), exoenzyme U (encoded by *exoU* gene). *ExoA* is the major constituent of the type II secretion system (T2SS) which inhibits protein synthesis through the transfer of the adenosine diphosphate-ribosyl moiety from nicotinamide-adenine dinucleotide to elongation factor 2, resulting in the inhibition of protein. Another important virulence factor that was recently recognized is the type III secretion system (T3SS). T3SS is a contact-dependent protein secretion pathway that plays a major role in the pathogenesis of serious *P. aeruginosa* infections. This system secretes effector proteins such as *ExoS* and *ExoU* (12). *ExoS* is a major cytotoxin that is required for colonization, invasion and bacterial dissemination during infection (2, 7, 13). *ExoU* is a cytotoxin with phospholipase activity that affects epithelial cells and causes lung infection (14). In addition, *exoU* has a toxic effect on macrophages (11, 12). One of the most important virulence determinants of this bacterium is the biofilm which is sessile populations of microorganisms that are enclosed by the self-secreted extracellular polysaccharide matrix or slime layer. Biofilms act as efficient barriers against antimicrobial agents (4). Multi-drug resistant forms of *P. aeruginosa* (MDRPA) are a major source of nosocomial infections (15). The increasing resistance of *P. aeruginosa* to nu-

merous antibiotics, because of excessive antibiotic administration, is now leading to the accumulation of antibiotic resistance and cross-resistance between antibiotics and the appearance of multidrug-resistant (MDR) forms of *P. aeruginosa* (16). It has been shown in previous studies that MDR strains are widespread among Iranian hospitals (2). The purpose of this study was to investigate the presence of *toxA*, *exoU* and *exoS*, the determination of biofilm production and antimicrobial susceptibility patterns among *P. aeruginosa* in Bandar Abbas, southern part city of Iran.

## MATERIALS AND METHODS

**Bacterial isolates and identification test.** In this cross-sectional study, undertaken from April 2017 to July 2017, 75 non-duplicates isolates of *P. aeruginosa* were obtained from patients admitted to Shahid Mohammadi and Pediatrics Hospitals at Bandar Abbas. Bacterial isolates were collected from different clinical samples such as wounds, respiratory tract, urine, blood, sputum, eye and CSF. Each isolate was cultured in MacConkey agar and Blood agar and plates were incubated at 37°C overnight. Isolates were identified using biochemical tests (8). All bacterial isolates were stored in a micro tube containing tryptic soy broth (TSB) with 20% glycerol at -70°C until further investigation (8, 14).

**Antibiotic susceptibility tests.** Antimicrobial susceptibility of the isolates was determined by the Kirby-Bauer disk diffusion method on Muller-Hinton (Merck, Germany) agar according to Clinical and Laboratory Standards Institute (CLSI) guideline (17). Briefly, a suspension of each isolates was adjusted to a turbidity equivalent to 0.5 McFarland and inoculated on Muller-Hinton agar plate. The tested antimicrobial agents were as follows: piperacillin (100 µg), ceftazidime (30 µg), meropenem (10 µg), imipenem (10 µg), gentamicin (10 µg), amikacin (30 µg), ofloxacin (30 µg), cefotaxime (30 µg), colistin (10 µg), ciprofloxacin (5 µg), tetracycline (75 µg) and aztreonam (30 µg) (MAST, Group Ltd, Merseyside, UK) (8, 13). *E. coli* ATCC 25922 and *P. aeruginosa* ATCC 27853 were used as standards in disk diffusion. The plates were incubated overnight at 35°C and the results were interpreted as susceptible, intermediate or resistant according to the criteria recom-

mended by the CLSI (2). MDR isolates were defined if they showed simultaneous resistance to one agent from three antibiotics group (18).

**Identification of bacterial isolates as *P. aeruginosa* by PCR.** To approve bacterial isolates as *P. aeruginosa*, all isolates were checked for the presence of *gyrB* gene with specific primers as detailed in Table 1 (19).

**Extraction of DNA.** DNA was extracted from the isolates by the modified TE boiling method. Each sample was suspended in 200 µL of TE buffer [10 mM/L Tris-HCl, 1 mM/L EDTA (pH 7.5)]. Each suspension was centrifuged at 8000 rpm for 4 min at 4°C 3 times. The pellet was re-suspended in 200 µL TE buffer, mixed on a vortex mixer and subjected to boiling at 100°C in a heating block (Boeco, Germany) for 1 min. Three freeze-thaw cycles were performed alternating between -70°C for 3 min and 100°C for 2 min. The tubes were centrifuged at 10000 rpm for 5 min. The supernatant was transferred to a sterile tube and stored at -20°C (20).

**Polymerase chain reaction amplifications.** PCR was carried out to detect *toxA*, *exoU* and *exoS*. The final volume of each reaction was 25 µL, containing 2 µL of DNA, 1× PCR buffer, 2 mM MgCl<sub>2</sub>, 200 µM of dNTP, 0.2 µM each of primer and 1 U Taq polymerase (SinaClon, Iran). PCR amplification for *toxA*, *exoU* and *exoS* genes were performed according to the following program: initial denaturation at 94°C for 5 min; 30 cycles of denaturation at 94°C for 30 s; annealing of *toxA* at 60°C, *exoU* at 56°C and *exoS* at 58°C for 50 s; extension at 72°C for 50 s; and a final extension step at 72°C for 10 min. For staining of the gel, each PCR product was mixed with 5× Gel Red (Biotium, USA) and then separated on electrophore-

sis on 1.2% agarose gel in TBE buffer (7.5 g EDTA, 108 g Tris and 55 g boric acid). After electrophoresis, they were visualized under UV transilluminator. One PCR product was sequenced for each gene and then used as a positive control in PCR reactions. Sequences were submitted to the GenBank. Nucleotide sequence database under accession numbers: LT615361 for *toxA*, LT615362 for *exoS* and LT628504 for *exoU*.

**Biofilm formation.** All isolates were analyzed for their abilities to produce biofilm using a colorimetric microtiter method. In order to quantitatively determine biofilm formation capacity, bacterial colonies were grown overnight at 37°C in Tryptic Soy Broth (TSB) (Merck Darmstadt, Germany). The bacterial suspensions were diluted (1:100) in a new TSB medium and 150 µL of this solution was inoculated onto the sterile flat-bottomed 96-well polystyrene microtiter plates. After incubation for 24 h at 37°C, the wells were gently washed three times with distilled water. The wells were dried in an inverted position at room temperature and finally stained with 125 µL of 0.1% crystal violet solution (CV) in water for about 10-15 min. Crystal violet was discarded; and to remove extra CV, the wells were washed three times. Finally, the bounded CV was released by the addition of 125 µL of 30% acetic acid. A new sterile plate was inoculated with 125 µL destaining solutions in each well. The absorbance of optical density (OD) of each well was measured at 550 nm using an ELISA reader (Biotek elx800). All the assays were repeated three times. As a control, the un-inoculated medium was used to determine background OD. The cut-off OD (OD<sub>c</sub>) was defined as three standard deviations above the mean OD of the negative control. According to the results of the microtiter plate test, the isolates were classified into the following four

**Table 1.** Primers used in this study

Primer Target	Oligonucleotide Sequence (5'-3')	Amplicon Size (bp)	Target Gene	TM °C	References
<i>toxA</i> -F	TGCTGCACTACTCCATGGTC	190	<i>toxA</i>	53.8	(24)
<i>toxA</i> -R	ATCGGTACCAGCCAGTTCAG			53.8	
<i>exoU</i> - F	GCTAAGGCTTGGCGGAATA	204	<i>exoU</i>	51.1	(10)
<i>exoU</i> -R	AGATCACACCCAGCGGTAAC			53.8	
<i>exoS</i> - F	ATGTCAGCGGGATATCGAAC	230	<i>exoS</i>	51.1	(10)
<i>exoS</i> -R	CAGGCGTACATCCTGTTCCT			53.8	

categories based on the optical density: non-biofilm producers (OD test <ODc), weak biofilm producers (ODc < OD < 2× ODc), moderate biofilm producers (2× ODc < OD < 4X ODc) and strong biofilms producers (4× ODc < OD) (21, 22).

**Statistical analysis.** Statistical Package for Social Sciences (SPSS) software version 23 was used for statistical analyses. The correlation between the prevalence of the virulence gene, antibiotic resistance patterns, and biofilm production were determined using Pearson’s Chi-square test. A P value of < 0.05 was considered to be statistically significant.

**RESULTS**

The rate of bacteria from each sample was as follows: urine 31.5%, respiratory tract sample 28.5%, wounds 20%, blood 8.6%, eye 7.1% and CSF 4.3%. The resistance pattern to the 12 antimicrobials tested is shown in Table 2. According to the results, a high rate of resistance was observed for tetracycline (32.85%) and ofloxacin (30%). The low resistance was observed for colistin (1.42%). One isolate (1.42%) was resistant to all the tested antibiotics. In addition, 58.6% of the isolates were sensitive to all the antimicrobial agents. In total, 24.3% of the isolates showed resistance to at least three different classes of antimicrobial agents and were identified as MDR. Amplification analysis showed that 95.7,

55.7 and 38.6% of the samples harbored *tox*A, *exo*S and *exo*U, respectively. The co-existence of *exo*S and *exo*U was detected in 4.28% of the isolates (Table 3). *exo*U and *exo*S genes were significantly prevalent in the urine and wound isolates, respectively. Biofilm data showed that 98.6% of the isolates were biofilm producers, in which, 60% were strongly biofilm producers and the rates of moderate and weak biofilm producers were 34.3 and 4.3%, respectively. However, biofilm formation was not found in 1.4% of the isolates. Interestingly *exo*S and *exo*U positive strains had a significantly higher ability to form biofilm.

**DISCUSSION**


*P. aeruginosa* is an important opportunistic cause of nosocomial infections and it has developed resistance to ranges of antimicrobial agents in immunocompromised patients (1, 2). In *P. aeruginosa* infections, biofilm production has been observed as an important determinant of pathogenicity. The formation of biofilms facilitates chronic bacterial

**Table 3.** Frequency of exoenzymegenes

	<i>exo</i> S		Total
	Yes	No	
<i>exo</i> U Yes	3 (4.28)	24 (34.28)	27 (38.57)
<i>exo</i> U No	36 (51.42)	7 (10)	43 (61.42)
Total	39 (55.71)	31 (44.28)	70 (100)

**Table 2.** Antimicrobial resistance pattern of *P. aeruginosa* isolates

Samples	Antibiotic											
	Gentamicin	Imipenem	Ceftazidim	Aztreonam	Ciprofloxacin	Amikacin	Colistin	Ofloxacin	Tigecyclin	Piperacilin	Meropenem	Tetracyclin
Urine	2	3	2	2	4	2	0	5	1	1	1	3
Blood	2	2	2	2	2	2	0	2	3	2	2	5
Wound	2	3	2	2	2	2	0	4	0	0	3	3
Respiratory	3	5	8	4	3	2	0	7	6	3	5	9
Eye	0	0	0	0	0	0	0	0	0	0	1	0
CSF	3	3	3	3	3	3	1	3	1	3	3	3
Total	12	16	17	13	14	11	1	21	11	9	15	23
(%)	(17.14)	(22.85)	(24.28)	(18.57)	(20)	(15.71)	(1.42)	(30)	(15.71)	(12.85)	(21.42)	(32.85)



**Fig 1.** Electrophoresis results of virulence genes PCR  
Lane 1: ladder 100 bp, lane 2: *toxA*, lane 3: *exoU*, lane 4: *exoS* and lane 5: negative control

infections and reduces the efficacy of antimicrobial therapy (1, 13). According to the results of this study, 98.6% of the *P. aeruginosa* isolates produced biofilms, and among them, 60% were strong biofilm producers. Our results showed 68% of isolates with strong biofilm were resistant to tetracycline. In a study by Ghanbarzadeh et al. and Jabalameli et al. respectively, in Iran, 92.4 and 96.9% of the isolates produced biofilm, which are in accordance with the results of this study (2, 9). It is noteworthy that the rate of strong biofilm production in urine samples (65%) was higher than other samples. The study of the relationship between biofilm formation and antibiotic resistance showed that MDRPA isolates produced strong biofilm. In recent years, several reports confirmed an increasing multidrug resistance among *P. aeruginosa* isolates from nosocomial infections in Iranian hospitals (15). In this study, only 1.4% of the isolates were resistant to colistin. This finding showed that this antibiotic could be used in first line for the treatment of infections due to *P. aeruginosa*. Unfortunately, colistin is the last choice of therapy for these infections. Recently, colistin resistance to

*P. aeruginosa* has been reported from different parts of the world. Interestingly, 58.6% of the total isolates were sensitive to all antibiotic agents. In contrast to other studies that showed a high prevalence of antibiotic resistance, in this study, lower prevalence of antibiotic resistance was observed. *P. aeruginosa* secretes effector proteins such as *exoS*, *exoU* and *toxA*. In isolates with strong biofilm, 58.82%, 32.35% and 29.41% of them were positive for *toxA*, *exoS* and *exoU* genes, respectively. These proteins modify host cell functions, which are important in cytoskeletal organization and signal transduction. *ExoS* is a bi-functional toxin exhibiting ADP-ribosyltransferase and GTPase-activating activity. *ExoU* exhibits phospholipase activity and disrupts eukaryotic membranes following its delivery into the cytoplasm. In our investigation, 100% of the *P. aeruginosa* isolates from the eye and the wound samples were *toxA*+, which is the same as Yousefi-Avarvand et al.'s study (14). *ToxA* was the most frequent (95.7%), which is higher than Ghanbarzadeh's (75%) and Amirmozafari's (81%) studies (2, 13). In a study from Iran, Yousefi-avarvand reported 65.4 and 66.7% for *exoU* and *exoS*, respectively, and this is higher than that of the current study (14). Firouzi-Dalvand and Pooladi reported the rates of *exoU* (22%) and *exoS* (14%) in burn samples, so, their findings for the genes are less than those of the current study (10). In Poland, Pobiega reported a rate for *exoU* (19.2%) and *exoS* (92.3%) (12). In a research in Iran by Heidary, the frequency of *exoS* and *exoU* among the clinical isolates of *P. aeruginosa* was 92.95 and 56.33%, respectively, which is in contrast to this study. However, the frequency of *exoU* in the current study is comparable to that of Habibi and Honarmand's study (37.5%) (23).

## CONCLUSION

In conclusion, this study showed that the exotoxin A and exoenzyme S and U genes are commonly disseminated among the *P. aeruginosa* isolates from patients bed fast in hospitals. Moreover, a high rate of biofilm producer isolates were found in urine samples, which is a serious problem in the treatment of urinary tract infections. Additional studies are necessary on other virulence factors to obtain more information about *P. aeruginosa*, in order to find a way to diagnose and treat infections more quickly.

## REFERENCES

- Azimi S, Kafili HS, Baghi HB, Shokrian S, Najaf K, Asgharzadeh M, et al. Presence of *exoY*, *exoS*, *exoU* and *exoT* genes, antibiotic resistance and biofilm production among *Pseudomonas aeruginosa* isolates in Northwest Iran. *GMS Hyg Infect Control* 2016;11:Doc04.
- Ghanbarzadeh Corehtash Z, Khorshidi A, Firoozeh F, Akbari H, Mahmoudi Aznavah A. Biofilm formation and virulence factors among *Pseudomonas aeruginosa* isolated from burn patients. *Jundishapur J Microbiol* 2015;8(10):e22345.
- Amirmozafari N FMJ, Habibi A. Association of the Exotoxin A and Exoenzyme S with antimicrobial resistance in *Pseudomonas aeruginosa* strains. *Arch Iran Med* 2016;19:353-358.
- Yousefi-Avarvand RK A, Sedigh Ebrahim-Saraie H, Emami A, Zomorodian K, Motamedifar M. The frequency of Exotoxin A and Exoenzymes S and U genes among clinical isolates of *Pseudomonas aeruginosa* in Shiraz, Iran. *Int J Mol Cell Med* 2015;4: 167-173.
- Faraji F, Mahzounieh M, Ebrahimi A, Fallah F, Teymournejad O, Lajevardi B. Molecular detection of virulence genes in *Pseudomonas aeruginosa* isolated from children with Cystic Fibrosis and burn wounds in Iran. *Microb Pathog* 2016;99:1-4.
- Habibollahi MM, Abbasi M, Abedi Gh, Dabighi MM. Molecular evaluation of *Pseudomonas aeruginosa* isolated from patients in burn ward, ICU, CCU and ITU in a number of hospitals in Kerman province. *JLS* 2015;5 (S2):1428-1431.
- Javadi YS A, Khodadadian R, Fakharian F, Morovvati A, Abedzadeh A, dastjani Farahani F, et al. Comparison the presence of exotoxin A, T, S isolated from clinical and environmental sample *Pseudomonas aeruginosa* in hospitals of Qom city. *RJFH* 2015;10: 709-713.
- Jabalameli F, Mirsalehian A, Khoramian B, Aligholi M, Khoramrooz SS, Asadollahi P, et al. Evaluation of biofilm production and characterization of genes encoding type III secretion system among *Pseudomonas aeruginosa* isolated from burn patients. *Burns* 2012;38:1192-1197.
- Firouzi-Dalvand L, Pooladi M. Identification of *exoS*, *exoU* genes in *Pseudomonas aeruginosa*. *JPS* 2014;5:89-95.
- Georgescu M, Gheorghe I, Curutiu C, Lazar V, Bleotu C, Chifiriuc M-C. Virulence and resistance features of *Pseudomonas aeruginosa* strains isolated from chronic leg ulcers. *BMC Infect Dis* 2016;16:92.
- Pobiega M, Maciag J, Chmielarczyk A, Romaniszyn D, Pomorska-Wesolowska M, Ziolkowski G, et al. Molecular characterization of carbapenem-resistant *Pseudomonas aeruginosa* strains isolated from patients with urinary tract infections in Southern Poland. *Diagn Microbiol Infect Dis* 2015;83:295-297.
- Amirmozafari N, Fallah Mehrabadi J, Habibi A. Association of the exotoxin A and exoenzyme S with antimicrobial resistance in *Pseudomonas aeruginosa* strains. *Arch Iran Med* 2016;19:353-358.
- Yousefi-Avarvand A, Khashei R, Sedigh Ebrahim-Saraie H, Emami A, Zomorodian K, Motamedifar M. The frequency of Exotoxin A and Exoenzymes S and U genes among clinical isolates of *Pseudomonas aeruginosa* in Shiraz, Iran. *Int J Mol Cell Med* 2015;4:167-173.
- Magalhães MJTL, Pontes G, Serra PT, Balieiro A, Castro D, Pieri FA, et al. Multidrug resistant *Pseudomonas aeruginosa* survey in a stream receiving effluents from ineffective wastewater hospital plants. *BMC Microbiol* 2016;16:193.
- Yayan J, Ghebremedhin B, Rasche K. Antibiotic resistance of *Pseudomonas aeruginosa* in pneumonia at a single University hospital center in Germany over a 10-Year Period. *PLoS One* 2015;10(10):e0139836.
- Clinical and Laboratory Standards Institute (CLSI) (2016): Performance standards for antimicrobial susceptibility testing; Twenty-sixth informational supplement. CLSI document M100-S26. Wayne, PA: CLSI.
- Magiorakos AP, Srinivasan A, Carey RB, Carmeli Y, Falagas ME, Giske CG, et al. Multidrug-resistant, extensively drug-resistant and pandrug-resistant bacteria: an international expert proposal for interim standard definitions for acquired resistance. *Clin Microbiol Infect* 2012;18:268-281.
- Anuj SN, Whiley DM, Kidd TJ, Bell SC, Wainwright CE, Nissen MD, et al. Identification of *Pseudomonas aeruginosa* by a duplex real-time polymerase chain reaction assay targeting the *ecfX* and the *gyrB* genes. *Diagn Microbiol Infect Dis* 2009;63:127-131.
- Faridi F, Sedigheh J. REP-PCR typing, antibiogram pattern and distribution of clinical isolates of *Pseudomonas aeruginosa* in a teaching hospital in South of Iran. *Mol Med* 2015;1:47-55.
- O'Toole GA. Microtiter dish biofilm formation assay. *J Vis Exp* 2011;(47): 2437.
- Hassan A, Usman J, Kaleem F, Omair M, Khalid A, Iqbal M. Evaluation of different detection methods of biofilm formation in the clinical isolates. *Braz J Infect Dis* 2011;15:305-311.
- Habibi A, Honarmand R. Profile of Virulence Factors in the multi-drug resistant *Pseudomonas aeruginosa* strains of human urinary tract infections (UTI). *Iran Red Crescent Med J* 2015;17(12): e26095.
- Imani Foolad AA HM, Mousavi SF. Association between exotoxin A (*exo-A*) gene and antibiotic resistance pattern with biofilm formation in *Pseudomonas aeruginosa*. *J Ardabil Univ Med Sci* 2011;11:7-13.